RLYB · Rallybio Corporation · Stock research

Current Thesis

Nothing has entered the public file since the 2026-08-06 10-Q. As of 2026-08-23 the Form S-4 filed 2026-07-15 has not been declared effective, no amendment to it appears in the public filing record, and no record date or special-meeting date exists. Thirty-nine days of SEC calendar have passed with the docket quiet.

So the situation stands where the last two filings left it. The S-4 carries Rallybio Net Cash of approximately $83.2M at 2026-06-30, down from ~$87.7M at 2026-03-31. The 10-Q carries $92.8M cash and equivalents, $98.1M total assets, $3.6M total liabilities and 5,306,894 shares outstanding at the same date, with Q2 net income of $43.7M on the $50.0M Candid Therapeutics termination fee received 2026-05-04 against a $5.7M Q2 operating loss and $14.4M for the first half.

Dividing the S-4 figure by the 10-Q share count gives roughly $15.68 per share — arithmetic on two filed numbers, not a disclosed distribution amount. The 2026-08-21 close of $16.83 sits about 7% above that, with the 52-week high at $17.00. What a buyer is paying for above the cash line is the CVR, the 2.8% Avenzo stub and the assumption that the deal closes without a Net Cash haircut. The pile itself no longer comes at a discount.

Bullish and bearish views on Rallybio Corporation

The model's bull view on Rallybio Corporation (RLYB), in brief: The pile is unlevered and disclosed. 10-Q 2026-08-06: $92.8M cash against $3.6M total liabilities, with no marketable securities left to mark — the $23.4M held at 2025-12-31 matured during the period. The distribution mechanism is written down. The 2026-07-15 S-4 specifies… The bear view: The May–June discount is gone. Net Cash decays into the close. The company's own estimate stepped down $4.5M between the 3/31/26 and 6/30/26 marks. A close "prior to the end of 2026" implies two more quarterly steps plus transaction, legal and wind-down costs before anything is… Both cases follow in full.

Bull Case

• The pile is unlevered and disclosed. 10-Q 2026-08-06: $92.8M cash against $3.6M total liabilities, with no marketable securities left to mark — the $23.4M held at 2025-12-31 matured during the period.
• The distribution mechanism is written down. The 2026-07-15 S-4 specifies "Parent Distributions" of substantially all Net Cash to pre-closing securityholders, with up to $50M declarable before the stockholder meeting.
• The CVR window is five years. One non-transferable CVR per pre-closing share, entitling holders pro rata to net proceeds from legacy-asset dispositions and Recursion payments through 2031-12-31, subject to a $1M minimum distribution threshold.
• A quiet docket is consistent with a light review. No S-4/A has been filed in the 39 days since 2026-07-15. That is an inference about SEC comment traffic, not a disclosure — but the shorter path to the 45-calendar-day meeting clock runs through no re-filing.
• Financing was the smallest variable and remains so. The $215.0M concurrent private placement announced 2026-06-01 was described as oversubscribed, with Blackstone Multi-Asset Investing, accounts advised by T. Rowe Price Investment Management, Vivo Capital, OrbiMed, Affinity Asset Advisors and ADAR1 Capital Management.
• Break protection is asymmetric. Avenzo owes $20.0M on certain terminations ($8.0M after the End Date) plus up to $750K expenses, against $600K flowing the other way. This board already banked a $50.0M break fee on 2026-05-04 when Candid walked to UCB.
• Stub terms are fixed at the top of the document: Avenzo at $300.0M, Rallybio at $15.0M post-distribution, exchange ratio 0.5020, pro forma ownership 56.6% Avenzo / 40.6% financing / 2.8% legacy. Clinical anchor: AVZO-021 (selective CDK2) at ASCO 2026-06-01 — 5.3-month median PFS in HR+/HER2− patients with a median of four prior lines, with the financing stated to fund operations into late 2028.

Bear Case

• The May–June discount is gone.
• Net Cash decays into the close. The company's own estimate stepped down $4.5M between the 3/31/26 and 6/30/26 marks. A close "prior to the end of 2026" implies two more quarterly steps plus transaction, legal and wind-down costs before anything is distributed.
• The distribution is capped and conditional. Per the S-4, only one Parent Distribution may occur before the stockholder meeting, capped at $50M declared pre-meeting, and the final amount may be lower or zero.
• Every downstream date floats. No effectiveness order, no record date, no meeting notice as of 2026-08-23. The meeting is due within 45 calendar days of effectiveness, so a September effectiveness pushes the vote toward late October and the close into the last weeks of the year.
• The 2.8% is not fixed. The 0.5020 exchange ratio adjusts on final Net Cash and share count at closing, so both the cash return and the stub move with the same variable.
• Any adverse 8-K reprices this in a gap.

Setup & Price Structure

• Reference prices: last completed daily close $16.83 (2026-08-21); 52-week high $17.00; -1.0% from that high; RSI(14) 66.5; a three-month price change of +6.0%.
• Drift, not trend. From $16.99 on 2026-08-14 to $16.83 on 2026-08-21 is about 1% over five sessions while the registration clock ran. Price is pinned near the top of its range with no new information arriving.
• The narrative is maturing. The informational peak was 2026-07-15 (S-4 Net Cash) and 2026-08-06 (10-Q balance sheet); the last press headline is 2026-06-01, 83 days back. The name still works — within 1% of the 52-week high — but the flow that re-rated it from a sub-cash quote is spent, and the marginal buyer is now underwriting completion rather than discovering a discount. It flips to saturated if this shelf holds into October with no effectiveness order, because at that point the premium is being paid purely for elapsed time.
• Positioning observables. Three Schedule 13G/A ownership amendments are dated 2026-08-14 in the public filing record; that is the standard 45-day post-quarter deadline, so their timing is a calendar artifact. Director Helen M. Boudreau's Form 4 filed 2026-07-10 reports an exercise of 3,562 options at $2.38 on 2026-07-06, taking reported holdings to 6,542 shares, with no sale disclosed alongside it. There is no imminent earnings print — the next 10-Q is due around 2026-11-10. Rallybio itself has issued no equity into the move; the $215.0M placement sits at the Avenzo level and is priced with the deal.
• Structure of the payoff. Upside is bounded by the document — cash near the $15.68 arithmetic, plus a CVR with a $1M threshold and a 2.8% stub carried at $15.0M — while a termination reopens the whole range below. RSI in the mid-60s at a 52-week high in a name whose upside is capped by filed arithmetic is momentum without a numerator.

Catalyst Calendar (next 30 days)

• ~2026-09-15 (est.) — SEC declaring the 2026-07-15 Form S-4 effective. No date is set as of 2026-08-23. This is the gate on every other date.
• Any date, unscheduled — a Form S-4/A amendment. If the SEC has issued comments, the amendment is the first visible artifact; none has appeared in 39 days.
• ~2026-09-22 (est.) — record date and special-meeting notice, reachable inside the window only if effectiveness lands by mid-September.
• Outside the 30-day window but on the same chain: ~2026-10-31 (est.) special meeting with a possible pre-vote Parent Distribution declaration; ~2026-11-10 (est.) Q3 10-Q with the next disclosed Net Cash mark; 2026-12-31 as the outer edge of the stated expectation to close before year-end.

What Would Change Our Mind

The clock breaks first. If 2026-09-30 arrives with the 2026-07-15 registration statement still not effective and no meeting notice on file, a Q4 close stops being the base case and each additional quarter subtracts burn from the distributable pile — the disclosed step between 3/31/26 and 6/30/26 was $4.5M.

The second break is the number itself. A declared Parent Distribution materially below the $83.2M reference, or a meeting held with no distribution declared, removes the arithmetic the current price leans on. So would a Q3 10-Q Net Cash mark stepping down by more than $4.5M.

On price, a weekly close below $14 ends the read: that level sits under the per-share arithmetic on the S-4's $83.2M at 2026-06-30 and would say the market is discounting a break or a haircut rather than a completion.

Improvement runs the other way and is equally observable: an effectiveness order plus a declared distribution at or near the June-30 mark restores a defined floor under the price and turns the remaining exposure into the CVR and the stub alone.

Correlation Notes

• While the deal is pending, this should not behave like biotech beta. The quote is anchored to a filed cash figure, so co-movement with XBI/IBB ought to be weak; the shared factor is deal-completion risk and the Q4 2026 biotech financing window in which the $215.0M placement has to fund.
• Recursion (RXRX) is the readable proxy for the CVR. REV102-related payments flow from Recursion, so its pipeline prioritisation disclosures are the observable that carries information about whether the CVR ever clears the $1M threshold.
• Post-close the correlation set changes wholesale. As AVZO the security becomes a clinical-stage CDK-inhibitor and bispecific-ADC oncology story trading with that cohort's data cycle, and the 2.8% legacy stake inherits whatever first-float discount reverse-merger listings take.
• Within the merger-arbitrage complex, the comparable is any cash-shell reverse merger where the pre-deal quote has closed its discount to net cash before the vote; the group's shared risk is a financing environment that reprices between signing and closing.